GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

Q3 2025 Earnings Call Transcript October 29, 2025 GSK plc beats earnings expectations. Reported EPS is $1.48, expectations ...

CHICAGO -- Adverse event risks varied across biologics used by asthma patients, an analysis of data submitted to the FDA ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

Notably, RI&I, oncology, and HIV treatments drove this growth. Benlysta and Nucala saw respective increases of 17% and 14%, while Jemperli sales continued their upward trajectory for the 10th ...

Cash generated from operations totaled £2.5 billion, with free cash flow of £1.2 billion. GSK declared a dividend of 16 pence ...

GSK raised its full-year guidance on Wednesday, after delivering stronger-than-expected third-quarter results, driven by ...

GSK plc raised its full-year 2025 guidance on Wednesday after posting a strong third quarter, reporting double-digit growth ...